Hematologic Monitoring in Chemotherapy for Patients with Gynecologic Cancer.
- Author:
Woo Ig SON
;
Seung Hee LEE
;
Jae Hoon KIM
;
Whi KIM
;
Kyung Keum SONG
;
Hyun Hong KIM
;
Ku Taek HAN
;
Hun Young LEE
- Publication Type:Original Article
- MeSH:
Bleomycin;
Bone Marrow;
Doxorubicin;
Drug Therapy*;
Equidae;
Gestational Trophoblastic Disease;
Granulocytes;
Humans;
Leukocytes;
Platelet Count
- From:Korean Journal of Gynecologic Oncology and Colposcopy
1993;4(3):63-70
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
A retrogpective review of hematologic rnonitoring involving aggressive chemotherapy was careiyd out ta assese whetber there ia a predictable relatiorship between the white blood ce11 count end the platelet count as a refleetion of bone marrow toxicity and when maximum myeloauppression occur during a treatment program. This data revealed that the white blood cell and granulocyte levels are closely related and that myeloeuppression can oceur during any course of CAP(cyclophosphamide, adriamycin, and cisplatin), VBP(vinblastine, bleomycin, and cisplatin) chemotherspy in gynecological cancer. Thus, for these treatment regimena in gynecoldgical malignancies, the white blood cell and granulocyte count is sufficient for momtoing toxicity and adjusting future courses of chemotherapy. There are no bone merrow depresaions by the treatment regirnens for the gestational trophoblastic disease.
